ArticleScientific reports2025

Triple therapy of RAS inhibitors, dapagliflozin, and finerenone in diabetic kidney disease patients with nephrotic-range proteinuria: a real-world study.

Chenjie Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.